நோவர்த்திச் நிறுவனங்கள் ஆஃப் உயிர் மருத்துவ ஆராய்ச்சி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Analyzing Encapsulated mRNA with LC, MS, and Calorimetry

Analyzing Encapsulated mRNA with LC, MS, and Calorimetry
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United statesNano lettNick zampaMatt lauberColette quinnJoe fredetteLamellar lipid matrices for parenteral administrationAcquity premier lc technology significantly improves sensitivityK berthelettewaters corporationNovartis institutes of biomedical researchOptimization of lipid nanoparticles for intramuscular administrationSurface hybrid technologyNanoparticles areNovartis institutesBiomedical researchWaters bioaccord

Chutes & Ladders—Genzyme vet Sherblom joins ReForm amid subcutaneous delivery shift

Chutes & Ladders—Genzyme vet Sherblom joins ReForm amid subcutaneous delivery shift
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSan franciscoSapna srivastavaChristine mellonStifel nicolausMichael kalosIntellia srivastavaShreehas tambeAbul abbasFraiser kansteinerDouglas swirskyOcuphire pharmaDaniel dolanWildon farwellBiocon biologics

Axcella Announces Alison D Schecter, M D , as President of R&D

Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakravarthy, M.D., Ph.D., has decided to step down as the company’s Chief Medical Officer to pursue another opportunity.

United kingdomUnited statesAlisond schecterIcahn school of medicine at mount sinaiDownstate health sciences universitySelecta biosciences incGlobal program head at baxaltaNovartis institutes of biomedical researchJj innovation centerCardiovascular research instituteManu chakravarthyChief medical officerBill hinshawChief executive officerSelecta biosciencesGlobal project head

Chutes & Ladders—After Verastem pit stop, bluebird vet Neumann lands at Kite

Editas Medicine James Mullen takes over as CEO from Feb. 15. Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon later snapped up by Thermo Fisher and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo and ex vivo gene edited medicines.” Collins joined Editas in 2019, picking up the role from

New yorkUnited statesBritish columbiaUnited kingdomBryan lakeSan franciscoBhardwaj desaiCynthia collinsPenrose therapeutxDaniel lynchShannon blalockFraiser kansteinerEli lillyPatrick mccallJosh smileyJoel sendek